Drug Trial Radar · NCT07279766
Effectiveness of mRNA-1273 Variant-Containing Vaccine Formulation Against Severe Outcomes in Adults Aged 50-64 Years Without Risk Factors for Severe COVID-19
Last checked: Nov 19, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
41,060
Actual
Start
Dec 11, 2025
Primary completion
Aug 26, 2026
Study completion Sep 5, 2026
Sponsor
- Lead sponsor
- Tor Biering-SørensenAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- ModernaTX, Inc.
- First posted
- Dec 12, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 50 years, up to 64 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this pragmatic randomized trial is to evaluate the vaccine effectiveness of the COVID-19 vaccine, mRNA-1273, in adults aged 50-64 years without known risk factors for severe COVID-19 infection. Participants will be randomized 1:1 to either COVID-19 vaccine or no COVID-19 vaccine.
Conditions
- COVID-19
Interventions
mRNA-1273 (Moderna COVID-19 vaccine)Biological
For this arm, the current variant formulation of Spikevax (mRNA-1273) vaccine will be used.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Medically attended COVID-19Time frame: ≥14 days after initially booked study visit date until 6 months after initially booked study visit date
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Center for Translational Cardiology and Pragmatic Randomized Trials, Department of Cardiology, Copenhagen University Hospital - Herlev and Gentofte
Hellerup, Denmark
Danske Lægers Vaccinations Service
Søborg, Denmark
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.